Kernel Flow and the need for neuroimaging data, Veterans Affairs studies psychedelic medicines, Colorado activists file psilocybin ballot initiative.
Psych Capital lists on Aquis Exchange, Australian Capital Territory to decriminalise drug possession, EMCDDA releases annual report for 2022.
Psychedelic-assisted therapy at home, How psychedelic medicines might treat depression, Former Chief of Australian Defence Force advocates for MDMA therapy.
Oregon’s Psilocybin Services Act, British Columbia to decriminalise possession of illicit drugs, The UK’s opportunity in psychedelic healthcare.
Ceruvia on the mechanism of migraine, Psych Capital to list on Aquis Stock Exchange, US federal agency awards US$2.7m to develop psychedelic medicines.
PSYCH Symposium: London 2022, CSIRO shows support for psychedelic healthcare, Inside the dispute over a high-profile psychedelic study
EXCLUSIVE: Biomind Labs' relocation to the UK, Psychedelic research in the UK and Europe, Brain-scanning technology to test efficacy of psychedelic medicine.
Negev Capital and Investing in Psychedelic Healthcare, Landmark gathering of psychedelic executives and scientists in London, Marketing the future of healthcare
MindMed, MM-120 and Dynamic Drug Development; Making psilocybin available to UK cancer patients; Oregon to only allow cultivation of psilocybe cubensis.
Bicycle Day; Are psychedelic stocks reaching the bottom as bad investors bail?; MindMed to present clinical trial results at PSYCH Symposium
Mental health and psychedelic medicine, Numinus Wellness acquires Novamind for C$26.2m, Psilocybin increases brain connectivity for up to three weeks
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.